Obgemsa (Vibegron)

Vibegron selectively activates β3‑adrenergic receptors located on the detrusor smooth muscle of the bladder. This activation causes muscle relaxation, which expands functional bladder capacity and suppresses involuntary contractions that trigger urgency and frequent urination.

The specific dose of Obgemsa is determined by the prescribing healthcare professional based on individual patient factors. The prescriber will select the appropriate strength and dosing schedule according to clinical guidelines and patient response.

Safety data for Vibegron in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To request Obgemsa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative class for overactive bladder is antimuscarinic agents such as oxybutynin. Compared with antimuscarinics, Vibegron (Obgemsa) has a different mechanism—β3‑adrenergic stimulation—and generally shows a lower incidence of dry mouth and constipation, though individual response may vary.

Obgemsa should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Obgemsa is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include urinary retention, severe hypertension, allergic reactions such as rash or anaphylaxis, angioedema, and cardiac arrhythmias including QT prolongation. Patients should seek immediate medical attention if they experience difficulty urinating, a rapid rise in blood pressure, or signs of an allergic response.

Obgemsa is contraindicated in patients with known hypersensitivity to Vibegron or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, severe hepatic impairment, or those taking other β3‑adrenergic agonists. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.